Numerous media outlets reported on the AMR Action Fund’s investment in Centauri Therapeutics Limited.
CIDRAP reported that the financing “will help support the completion of phase 1 clinical studies for CTX-187, a novel antibiotic that employs a dual-mechanism action to target clinically prevalent and multidrug-resistant gram-negative bacteria.”
The article also quoted AMR Action Fund CEO Henry Skinner:
“The growing burden of drug-resistant Gram-negative infections is one of the most pressing challenges in global health, leaving patients with limited and increasingly ineffective treatment options," said AMR Action Fund CEO Henry Skinner, PhD. "Centauri’s approach represents a promising opportunity to address this challenge, and we are pleased to support the team as they advance toward first-in-human studies."